Abstract
After the discovery and characterization of the H3R and H4R receptors, they have become widely anticipated as potential therapeutic agents in the treatment of sleep disorders. In preliminary studies, histamine H3 receptor (H3R) antagonists and inverse agonists have demonstrated promise in the treatment of sleep disorders associated with excessive daytime sleepiness. This review article summarizes the current research in this area and characteristics of H3R and H3R antagonists and inverse agonists in development.
Keywords: Histamine, H3 receptor, H3R antagonists, histamine H3 receptor H3R inverse agonists, narcolepsy treatment, excessive daytime sleepiness, antihistamine, sleepiness, narcolepsy, metabotropic, tuberomammillary, diurnal, orexin, preoptic, accumbens, globus pallidus, substantia nigra, presynaptically, norepinephrine, thioperamide
Current Pharmaceutical Design
Title: Histamine H3 Receptor (H3R) Antagonists and Inverse Agonists in the Treatment of Sleep Disorders
Volume: 17 Issue: 15
Author(s): Meredith Broderick and Tony Masri
Affiliation:
Keywords: Histamine, H3 receptor, H3R antagonists, histamine H3 receptor H3R inverse agonists, narcolepsy treatment, excessive daytime sleepiness, antihistamine, sleepiness, narcolepsy, metabotropic, tuberomammillary, diurnal, orexin, preoptic, accumbens, globus pallidus, substantia nigra, presynaptically, norepinephrine, thioperamide
Abstract: After the discovery and characterization of the H3R and H4R receptors, they have become widely anticipated as potential therapeutic agents in the treatment of sleep disorders. In preliminary studies, histamine H3 receptor (H3R) antagonists and inverse agonists have demonstrated promise in the treatment of sleep disorders associated with excessive daytime sleepiness. This review article summarizes the current research in this area and characteristics of H3R and H3R antagonists and inverse agonists in development.
Export Options
About this article
Cite this article as:
Broderick Meredith and Masri Tony, Histamine H3 Receptor (H3R) Antagonists and Inverse Agonists in the Treatment of Sleep Disorders, Current Pharmaceutical Design 2011; 17 (15) . https://dx.doi.org/10.2174/138161211796197133
DOI https://dx.doi.org/10.2174/138161211796197133 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Diagnoses of Pathological States Based on Acetylcholinesterase and Butyrylcholinesterase
Current Medicinal Chemistry Conantokins Inhibitors of Ion Flow through the N-Methyl-D-Aspartate Receptor Channels
Current Drug Targets Polymer-Based Drug Delivery Devices for Neurological Disorders
CNS & Neurological Disorders - Drug Targets Anti-Endothelial Cell Antibodies in Patients with Cerebral Small Vessel Disease
Current Neurovascular Research Tyrosine Kinase Inhibitor as a new Therapy for Ischemic Stroke and other Neurologic Diseases: is there any Hope for a Better Outcome?
Current Neuropharmacology MTDL Design Strategy in the Context of Alzheimers Disease: From Lipocrine to Memoquin and Beyond
Current Pharmaceutical Design Metabotropic Glutamate Receptors in Central Nervous System Diseases
Current Drug Targets Nicotinic Receptors and the Treatment of Attentional and Cognitive Deficits in Neuropsychiatric Disorders: Focus on the α7 Nicotinic Acetylcholine Receptor as a Promising Drug Target for Schizophrenia
Central Nervous System Agents in Medicinal Chemistry The Role of the Endocannabinoid System in Alzheimers Disease: Facts and Hypotheses
Current Pharmaceutical Design Omega-3 Polyunsaturated Fatty Acids and Depression: A Review of the Evidence
Current Pharmaceutical Design Nitric Oxide Mimetic Molecules as Therapeutic Agents in Alzheimers Disease
Current Alzheimer Research Diagnostic Value of the Early Heart-to-Mediastinum Count Ratio in Cardiac 123I-mIBG Imaging for Parkinson's Disease
Current Radiopharmaceuticals Mitochondrial Biology and Neurological Diseases
Current Neuropharmacology Cerebral Amyloid Angiopathy: A Common Cause of Cerebral Hemorrhage
Current Medicinal Chemistry Lentiviral Vector-Based Models of Amyloid Pathology: From Cells to Animals
Current Alzheimer Research Multiple Hormonal Dysregulation as Determinant of Low Physical Performance and Mobility in Older Persons
Current Pharmaceutical Design COVID-19 Outbreak: Neurological Manifestations Beyond Cough and Fever
CNS & Neurological Disorders - Drug Targets Targeting Neurotrophic Signal Transduction Pathways in the Treatment of Mood Disorders
Current Signal Transduction Therapy Revisiting Antipsychotic-induced Akathisia: Current Issues and Prospective Challenges
Current Neuropharmacology Molecular and Biochemical Features in Alzheimers Disease
Current Pharmaceutical Design